Management of advanced neuroendocrine tumors with hepatic metastasis

Journal of Clinical Gastroenterology

Volumn 43, Issue 9, 2009, Pages 838-847

  Khasraw, Mustafa ^a   Gill, Anthony ^a   Harrington, Tim ^a   Pavlakis, Nick ^a   Modlin, Irvin ^b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Multimodality therapy; Neuroendocrine tumor; Sandostatin and fluoropyrimidines; TACE

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANTIEMETIC AGENT; BEVACIZUMAB; BORTEZOMIB; C PEPTIDE; CAPECITABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GASTRIN; GEFITINIB; GELFOAM; IMATINIB; INSULIN; IODINATED POPPYSEED OIL; MEDROXYPROGESTERONE ACETATE; MITOMYCIN C; OCTREOTIDE; PEGINTERFERON ALPHA; PERINDOPRIL; SOMATOSTATIN DERIVATIVE; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; ANGIOGRAPHY; ANTIANGIOGENIC ACTIVITY; ARTIFICIAL EMBOLISM; ASCITES; BIOLOGICAL THERAPY; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CASE REPORT; CHOLELITHIASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOGRAPHY; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; ISOTOPE LABELING; LIVER METASTASIS; LONG TERM CARE; LOOSE FECES; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PARACENTESIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEATORRHEA; STOMACH PARESIS; SYMPTOM; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEUROENDOCRINE TUMORS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 70349695874     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181b152a1     Document Type: Review

References (72)

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
2. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20:1-12.
3. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer. JCO. 2005;23:3706-3712. (Pubitemid 46252465)
4. Angeletti S, Corleto VD, Schillaci O, et al. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumors. Ital J Gastroenterol Hepatol. 1999;31:23-27. (Pubitemid 29103444)
5. Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase 1 trial in neuroendocrine neoplasms. Acta Oncol. 1993;32(2 suppl):217-223. (Pubitemid 23188539)
6. Arnold R, Neuhaus C, Benning R, et al. Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumours. World J Surg. 1993;17(4 suppl):511-519. (Pubitemid 23228405)
7. Kulke M. Clinical presentation and management of carcinoid tumors. Hematol Oncol Clin N Am. 2007;21:433-455. (Pubitemid 46843513)
8. Hobday TJ, Rubin J, Holen K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. 2007 ASCO Annual Meeting. Abstract No: 4504, 2007 ASCO Annual Meeting).
9. Yao JC, Phan AT, Chang, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. JCO. 2008;4311-4318.
10. DeLellis RA, Lloyd RV, Heitz PU, et al. World Health Organization Classification of Tumors Pathology and Genetics: Tumors of Endocrine Organs. Lyon: IARC Press; 2004.
11. Theriault RL. Hypercalcemia of malignancy: pathophysiology and implications for treatment. Oncology (Williston Park). 1993;7:47-50; discussion 52-55.
12. Barhoum M, Hutchins L, Fonseca VA. Intractable hypercalcemia due to a metastatic neuroendocrine tumor secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Am J Med Sci. 1999;318:203. (Pubitemid 30387255)
13. Landry CS, Scoggins CR, McMasters KM, et al. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97:253-258. (Pubitemid 351312166)
14. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro) endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008; 87:47-62. (Pubitemid 350308294)
15. Liapi E, Geschwind JF, Vossen JA, et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008;190:67-73.
16. Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18: 847-855. (Pubitemid 46963614)
17. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
18. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921-929.
19. South CD, Meyer MM, Meis G, et al. Yttrium-90 microsphere induced gastrointestinal tract ulceration. World J Surg Oncol. 2008;6:93.
20. Mazzaglia PJ, Berber E, Milas M, et al. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10-19. (Pubitemid 47042092)
21. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994;733:138-146.
22. Nilsson O, Kolby L, Wangberg B, et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer. 1998;77: 632-637. (Pubitemid 28059472)
23. Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315: 663-666. (Pubitemid 16055931)
24. Kvols L, Moertel C, Schutt A, et al. Treatment of the malignant carcinoid syndrome with a long-acting octreotide analogue (SMS 201-955): preliminary evidence that more is not better (abstract). Proc Am Soc Clin Oncol. 1987;6:95.
25. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci. 1989;34: 14S-27S. (Pubitemid 19086727)
26. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol. 1991;30:503-507.
27. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72:244. (Pubitemid 23182080)
28. Janson EM, Ahlstrom H, Andersson T, et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer. 1992;28A: 1647-1650.
29. Janson ET, Oberg K. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol. 1993;32:225-229.
30. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770-776. (Pubitemid 30091095)
31. Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther. 2003; 17:437-444. (Pubitemid 36259407)
32. Gulanikar AC, Kotylak G, Bitter-Suermann H. Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation? Transplant Proc. 1991; 23:2197-2198.
33. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90: 687-693. (Pubitemid 36760596)
34. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004; 151:107-112. (Pubitemid 39117371)
35. Arnold R, Rinke A, Müller H, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of Octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine MID gut tumors: a report from the PROMID Study Group. Proceedings of the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology. January 2009 [Abstract].
36. Scherubl H, Wiedenmann B, Riecken EO, et al. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer. 1994;30A: 1590-1591. (Pubitemid 24343028)
37. Eriksson B, Janson ET, Bax ND, et al. The use of new somatostatin analogues, lanreotide and octastatin, in neuro-endocrine gastro-intestinal tumours. Digestion. 1996;57 (suppl 1):77-80. (Pubitemid 26183928)
38. Ruszniewski P, Ducreux M, Chayvialle JA, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39:279-283. (Pubitemid 26276007)
39. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastro-intestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17:1111. (Pubitemid 29162933)
40. Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreo-tide LAR. Aliment Pharmacol Ther. 2000;14:557-560. (Pubitemid 30240747)
41. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23:412-415. (Pubitemid 32429157)
42. Rohaizak M, Farndon JR. Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumours. ANZ J Surg. 2002;72:635-638.
43. Canobbio L, Cannata D, Miglietta L, et al. Use of long-acting somatostatin analogue, lanreotide, in neuroendocrine tumors. Oncol Rep. 1994;1:129-131. (Pubitemid 2015097)
44. Faiss S, Rath U, Mansmann U. Ultra-high dose lanreotide treatoment in patients with metastatic neuroendocrine gastro-enteropancreatic tumors. Digestion. 1999;60:469-476. (Pubitemid 29401776)
45. Ducreux M, Ruszniewski M, Chayvialle J. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastro. 2000;95:3276-3281. (Pubitemid 30826308)
46. Ruszniewski P, Ish-Shalom S, Wymenga M, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004; 80:244-251. (Pubitemid 40187010)
47. Bajetta E, Procopio G, Catena L, et al. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer. 2006;107:2474-2481. (Pubitemid 44748532)
48. Frank M, Klose KJ, Wied M, et al. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol. 1999;94:1381-1387. (Pubitemid 29214657)
49. Oberg K. Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology. 2004;80(suppl 1):57-61.
50. Jodrell DI, Smith IE. Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study. Cancer Chemother Pharmacol. 1990;26:62-64. (Pubitemid 20122891)
51. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430-438. (Pubitemid 126423217)
52. van Hazel GA, Rubin J, Moertel CG. Treatment of metastatic neuroendocrine tumor tumor with dactinomycin or dacarbazine. Cancer Treat Rep. 1983;67:583-585.
53. Oberg K, Norheim I, Lundqvist G, et al. Cytotoxic treatment in patients with malignant neuroendocrine tumor tumors. Response to streptozocin- alone or in combination with 5-FU. Acta Oncol. 1987;26:429-432.
54. Oberg K, Norheim I, Alm G. Treatment of malignant neuroendocrine tumor tumors: a randomized controlled study of streptozocin Plus 5-Fu and human leukocyte interferon. Eur J Cancer Clin Oncol. 1989;25:1475-1479. (Pubitemid 19247456)
55. Vilar E, Salazar R, Pérez-García J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer. 2007;14: 221-232. (Pubitemid 47242624)
56. Hobday T, Rubin J, Goldberg R, et al. Molecular markers in metastatic gastrointestinal neuroendocrine tumors. Proc Am Soc Clin Oncol. 2003;22:A1078.
57. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316-1323.
58. Kulke M, Ryan D, Stuart K, et al. A phase II study of Temozolomide and Thalidomide in patients with metastatic neuroendocrine tumors. Presented in abstract form at the Chemotherapy Foundation Symposium XXI. New York, November 14, 2003.
59. Kulke M, Lenz H, Meropol N, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors. Proc Am Soc Clin Oncol. 2005;A4008. [Abstract].
60. Hurwitz H, Fehrenbacher L, Novotny WF, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
61. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26:3523-3529. Erratum in: J Clin Oncol. 2008;26:4697.
62. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544.
63. Van Essen M, Krenning EP, De Jong M, et al. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723-734. (Pubitemid 47123757)
64. Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology. 2008;87:8-19. (Pubitemid 350308290)
65. Gross DJ, Munter G, Bitan M, et al. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006;13:535-540. (Pubitemid 43886675)
66. Hobday T, Holen K, Donehower R, et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase ii consortium (P2C) study. J Clin Oncol ASCO Annual Meeting Proceedings 2006; 24:189s.
67. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004; 10:6111-6118. (Pubitemid 39287516)
68. Rothermel J, Wartmann M, Chen T, et al. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol. 2003;30:51-55. (Pubitemid 36712859)
69. Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer. 2004;101:934-939. (Pubitemid 39100425)
70. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006;51:1033-1038. (Pubitemid 44127047)
71. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95: 1148-1154. (Pubitemid 44660065)
72. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol. 2006;4: 526-547.